Doxorubicin

• 

  Subject Areas on Research

  • 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. 
  • 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. 
  • A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. 
  • A Novel Locus on 6p21.2 for Cancer Treatment-Induced Cardiac Dysfunction Among Childhood Cancer Survivors. 
  • A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. 
  • A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer. 
  • A colony color method identifies the vulnerability of mitochondria to oxidative damage. 
  • A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. 
  • A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. 
  • A genome-wide RNAi screen reveals multiple regulators of caspase activation. 
  • A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly. 
  • A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. 
  • A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. 
  • A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. 
  • A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. 
  • A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. 
  • A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease. 
  • A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. 
  • A quantitative study of the intracellular fate of pH-responsive doxorubicin-polypeptide nanoparticles. 
  • A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. 
  • A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. 
  • A synthetic mimic of the secretory granule for drug delivery. 
  • A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation. 
  • Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug. 
  • Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. 
  • Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status. 
  • Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. 
  • Adjuvant chemotherapy in older women with early-stage breast cancer. 
  • Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study. 
  • Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. 
  • Adriamycin in the treatment of childhood acute leukemia. A Southwest Oncology Group study. 
  • Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study. 
  • Adriamycin-Induced Podocyte Injury Disrupts the YAP-TEAD1 Axis and Downregulates Cyr61 and CTGF Expression. 
  • Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. 
  • Adult testicular sarcoma: presentation, evaluation, and treatment. 
  • Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. 
  • An in vitro assay procedure to test chemotherapeutic drugs on cells from human solid tumors. 
  • An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. 
  • An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. 
  • Anaplastic Thyroid Carcinoma, Version 2.2015. 
  • Anthracenedione activation by NADPH-cytochrome P-450 reductase; comparison with anthracyclines. 
  • Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. 
  • Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer. 
  • Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. 
  • Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells. 
  • Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal. 
  • Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy. 
  • Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model. 
  • CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. 
  • CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. 
  • Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. 
  • Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. 
  • Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. 
  • Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. 
  • Caspase-3 dependent cleavage and activation of skeletal muscle phosphorylase b kinase. 
  • Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. 
  • Chemotaxis-driven assembly of endothelial barrier in a tumor-on-a-chip platform. 
  • Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. 
  • Childhood hepatic mesenchymoma: successful treatment with surgery and multiple-agent chemotherapy. 
  • Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. 
  • Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. 
  • Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. 
  • Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 
  • Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. 
  • Clinical uses of pegylated pharmaceuticals in oncology. 
  • Clostridium septicum abscess in hepatic metastases: successful medical management. 
  • Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. 
  • Combination chemotherapy and radiation therapy of undifferentiated small cell bronchogenic carcinoma. 
  • Combination chemotherapy for osteosarcoma. 
  • Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. 
  • Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas. 
  • Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. 
  • Combined treatment approaches in regionally advanced bladder cancer. 
  • Commentary: Sympathectomy for cardiomyopathy: It's a matter of nerves. 
  • Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. 
  • Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae. 
  • Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. 
  • Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). 
  • Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. 
  • Complete discontinuity of the distal fistula tract from the developing gut: direct histologic evidence for the mechanism of tracheoesophageal fistula formation. 
  • Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. 
  • Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin. 
  • Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. 
  • Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. 
  • Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. 
  • Correlation of doxorubicin footprints with deletion endpoints in lacO of E. coli. 
  • Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. 
  • Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity. 
  • Creatine supplementation reduces doxorubicin-induced cardiomyocellular injury. 
  • Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. 
  • Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. 
  • Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia. 
  • Cytosolic accumulation of small nucleolar RNAs (snoRNAs) is dynamically regulated by NADPH oxidase. 
  • DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study. 
  • DNA sequence specificity of doxorubicin-induced mutational damage in uvrB- Escherichia coli. 
  • Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression. 
  • Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. 
  • Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study. 
  • Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. 
  • Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. 
  • Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. 
  • Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. 
  • Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. 
  • Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. 
  • Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. 
  • Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. 
  • Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. 
  • Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells. 
  • Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. 
  • Doxorubicin-conjugated chimeric polypeptide nanoparticles that respond to mild hyperthermia. 
  • Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma. 
  • Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. 
  • Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer. 
  • Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery. 
  • Dual-Energy CT Imaging of Tumor Liposome Delivery After Gold Nanoparticle-Augmented Radiation Therapy. 
  • Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. 
  • Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. 
  • Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. 
  • Effect of adriamycin and Corynebacterium parvum in tumor-bearing mice: modulation of response to sheep red blood cells. 
  • Effect of isopropyl-beta-D-thiogalactopyranosid induction of the lac operon on the specificity of spontaneous and doxorubicin-induced mutations in Escherichia coli. 
  • Effect of pazopanib on tumor microenvironment and liposome delivery. 
  • Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. 
  • Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. 
  • Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. 
  • Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. 
  • Efficacy of epidural blood patching or surgery in spontaneous intracranial hypotension: an evidence map protocol. 
  • Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. 
  • EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. 
  • Epirubicin: is it like doxorubicin in breast cancer? A clinical review. 
  • Epithelial Regeneration After Doxorubicin Arises Primarily From Early Progeny of Active Intestinal Stem Cells. 
  • Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. 
  • Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. 
  • Evaluating a critically ill patient with metabolic acidosis: the ifosfamide paradigm. 
  • Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. 
  • Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. 
  • Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice. 
  • Excision repair reduces doxorubicin-induced genotoxicity. 
  • Extracellular superoxide dismutase regulates cardiac function and fibrosis. 
  • FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. 
  • Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature. 
  • Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. 
  • Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. 
  • Fibroblast growth factor signaling in the developing tracheoesophageal fistula. 
  • Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). 
  • Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. 
  • Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. 
  • Follicular mucinosis as a presenting sign of acute myeloblastic leukemia. 
  • Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. 
  • Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study. 
  • Functional expression of the multidrug resistance-associated protein in the yeast Saccharomyces cerevisiae. 
  • Gelation of liposome interior. A novel method for drug encapsulation. 
  • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. 
  • Genetically Encoding Albumin Binding into Chemotherapeutic-loaded Polypeptide Nanoparticles Enhances Their Antitumor Efficacy. 
  • Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. 
  • Giant thoracic liposarcoma treated with induction chemotherapy followed by surgical resection. 
  • Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. 
  • Hair regrowth after cancer therapy. 
  • Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541. 
  • Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. 
  • High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. 
  • High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with multiply recurrent Wilms tumor. 
  • High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. 
  • High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. 
  • High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. 
  • High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. 
  • High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support. 
  • Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. 
  • Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. 
  • Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. 
  • How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? 
  • Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity. 
  • Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery. 
  • Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model. 
  • Hypertensive reactions associated with paclitaxel. 
  • Hyperthermia mediated liposomal drug delivery. 
  • IL-1 receptor signaling in podocytes limits susceptibility to glomerular damage. 
  • Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography. 
  • Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. 
  • Immune responses during administration of adriamycin and Corynebacterium parvum. 
  • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. 
  • Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. 
  • Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. 
  • Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. 
  • Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. 
  • Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples. 
  • Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. 
  • Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy. 
  • In Situ Proapoptotic Peptide-Generating Rapeseed Protein-Based Nanocomplexes Synergize Chemotherapy for Cathepsin-B Overexpressing Breast Cancer. 
  • In vitro chemotherapy testing of transitional cell carcinoma. 
  • In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma. 
  • In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. 
  • In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. 
  • In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. 
  • Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. 
  • Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. 
  • Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. 
  • Individual responses to chemotherapy-induced oxidative stress. 
  • Inflammatory breast carcinoma. Effective multimodal approach. 
  • Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. 
  • Inhibition of adriamycin-stimulated microsomal lipid peroxidation by mitoxantrone and ametantrone, two new anthracenedione antineoplastic agents. 
  • Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. 
  • Inhibitory effects of anthracenedione antineoplastic agents on hepatic and cardiac lipid peroxidation. 
  • Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. 
  • Interactions of chromatin context, binding site sequence content, and sequence evolution in stress-induced p53 occupancy and transactivation. 
  • Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. 
  • Intrinsic Xenobiotic Resistance of the Intestinal Stem Cell Niche. 
  • Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal. 
  • Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. 
  • Leiomyosarcoma in childhood and adolescence. 
  • Light scattering measurements of subcellular structure provide noninvasive early detection of chemotherapy-induced apoptosis. 
  • Lipid-coated microgels for the triggered release of doxorubicin. 
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. 
  • Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast. 
  • Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center. 
  • Long-term follow-up of survival in Hodgkin's lymphoma. 
  • Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. 
  • Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans. 
  • Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma. 
  • Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). 
  • Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). 
  • Lymphoblastic lymphoma in children--a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study. 
  • Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. 
  • Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. 
  • MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. 
  • MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. 
  • MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. 
  • Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. 
  • Management of locally advanced adenocarcinoma of the pancreas. 
  • Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration. 
  • Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin 
  • Measurement of the DNA synthetic capacity of activated lymphocytes: nucleotide triphosphate incorporation by permeabilized cells. 
  • Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. 
  • Mechanism-based engineering against anthracycline cardiotoxicity. 
  • Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. 
  • Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. 
  • Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. 
  • Metastatic thymoma with myasthenia gravis: complete remission with combination chemotherapy. 
  • MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. 
  • MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index. 
  • Mitoxantrone: propensity for free radical formation and lipid peroxidation--implications for cardiotoxicity. 
  • Modeling the Effect of TNF-α upon Drug-Induced Toxicity in Human, Tissue-Engineered Myobundles. 
  • Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. 
  • Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. 
  • Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. 
  • Modulation of glutathione peroxidase expression by selenium: effect on human MCF-7 breast cancer cell transfectants expressing a cellular glutathione peroxidase cDNA and doxorubicin-resistant MCF-7 cells. 
  • Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages. 
  • Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. 
  • N,N-dimethyladriamycin for treatment of experimental proliferative vitreoretinopathy: efficacy and toxicity on the rabbit retina. 
  • NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. 
  • Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity. 
  • Never underestimate a dermal lesion: reflections on a rare tumor. 
  • Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. 
  • Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. 
  • Nonlymphoblastic lymphoma in children--histology and stage-related response to therapy: a Pediatric Oncology Group study. 
  • Novel role of 4-hydroxy-2-nonenal in AIFm2-mediated mitochondrial stress signaling. 
  • Nutrition Modulation of Cardiotoxicity and Anticancer Efficacy Related to Doxorubicin Chemotherapy by Glutamine and ω-3 Polyunsaturated Fatty Acids. 
  • Ocular toxicity following high dose chemotherapy and autologous transplant. 
  • Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. 
  • Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin. 
  • Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. 
  • P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). 
  • PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. 
  • Paraneoplastic pemphigus associated with non-Hodgkin lymphoma. 
  • Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. 
  • Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. 
  • Pegfilgrastim: the promise of pegylation fulfilled. 
  • Peripheral T-cell lymphoma with unusual clinical presentation of rhabdomyolysis. 
  • Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma. 
  • Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. 
  • Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. 
  • Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. 
  • Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma. 
  • Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. 
  • Phase I evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. 
  • Phase I study of Doxil and vinorelbine in metastatic breast cancer. 
  • Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). 
  • Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. 
  • Phase I trial of interleukin-2 plus doxorubicin. 
  • Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. 
  • Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach. 
  • Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. 
  • Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B. 
  • Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332. 
  • Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. 
  • Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. 
  • Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. 
  • Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. 
  • Polycationic Nanofibers for Nucleic Acid Scavenging. 
  • Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. 
  • Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment. 
  • Post transfusion non-cardiogenic pulmonary edema in a patient with chemotherapy-related hemolytic uremic syndrome. 
  • Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. 
  • Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. 
  • Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. 
  • Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. 
  • Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. 
  • Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. 
  • Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. 
  • Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. 
  • Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. 
  • Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. 
  • Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. 
  • Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin. 
  • Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. 
  • Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. 
  • Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. 
  • RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin. 
  • Radiation techniques for the treatment of Hodgkin's disease with combined modality therapy or radiation alone. 
  • Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin. 
  • Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. 
  • Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. 
  • Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. 
  • Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. 
  • Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. 
  • Rational identification of a novel peptide for targeting nanocarriers to 9L glioma. 
  • Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 
  • Recombinant Synthesis of Hybrid Lipid-Peptide Polymer Fusions that Self-Assemble and Encapsulate Hydrophobic Drugs. 
  • Recombinant human tumor necrosis factor alone and with chemotherapeutic agents. Effect on nude mouse-supported human bladder cancer heterografts. 
  • Redox proteomic identification of HNE-bound mitochondrial proteins in cardiac tissues reveals a systemic effect on energy metabolism after doxorubicin treatment. 
  • Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. 
  • Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. 
  • Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. 
  • Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. 
  • Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. 
  • Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study. 
  • Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. 
  • Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. 
  • Ring current effects in adriamycin-flavin mononucleotide complexation as observed by 1H FT NMR spectroscopy. 
  • Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. 
  • Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. 
  • Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. 
  • Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. 
  • Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. 
  • Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. 
  • Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. 
  • Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice. 
  • Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). 
  • Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. 
  • Selective targeting of nanocarriers to neutrophils and monocytes. 
  • Self-assembled hybrid elastin-like polypeptide/silica nanoparticles enable triggered drug release. 
  • Self-assembling chimeric polypeptide–doxorubicin conjugate nanoparticles that abolish tumours after a single injection 
  • Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. 
  • Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. 
  • Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. 
  • Sickness behavior clustering in children with cancer. 
  • Simultaneous measurement of liposome extravasation and content release in tumors. 
  • Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. 
  • Small lymphocytic lymphoma presenting as a paraneoplastic syndrome with acute central nervous system demyelination. 
  • Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer. 
  • Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. 
  • Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. 
  • Stromal gene signatures in large-B-cell lymphomas. 
  • Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. 
  • Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. 
  • Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. 
  • Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. 
  • Symptomatic pulmonary allograft Kaposi's sarcoma in two lung transplant recipients. 
  • Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? 
  • Systemic anti-tumour effects of local thermally sensitive liposome therapy. 
  • Systemic chemotherapy for urothelial cancer. 
  • Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma. 
  • TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). 
  • Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. 
  • Targeted drug delivery by thermally responsive polymers. 
  • Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. 
  • Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. 
  • Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. 
  • The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. 
  • The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. 
  • The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. 
  • The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. 
  • The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. 
  • The manganese(III) porphyrin MnTnHex-2-PyP5+ modulates intracellular ROS and breast cancer cell migration: Impact on doxorubicin-treated cells. 
  • The materials engineering of temperature-sensitive liposomes. 
  • The molecular basis for complexation of adriamycin with flavin mononucleotide and flavin adenine dinucleotide. 
  • The patient experience of ABVD treatment in Hodgkin lymphoma: a retrospective cohort study of patient-reported distress. 
  • The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma. 
  • The role of cavitation in acoustically activated drug delivery. 
  • The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. 
  • The role of optimal debulking in advanced stage serous carcinoma of the uterus. 
  • The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. 
  • The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy. 
  • Therapeutic vaccines for aggressive B-cell lymphoma. 
  • Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. 
  • To oxidize or not to oxidize? 
  • Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy. 
  • Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. 
  • Treatment of high-stage bladder cancer: case for adjunctive chemotherapy. 
  • Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide. 
  • Treatment of superficial carcinoma of the bladder. 
  • Treatment of uterine leiomyosarcoma. 
  • Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. 
  • Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle-based Chemotherapy in Pten-deleted Mouse Models of Sarcoma. 
  • Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs. 
  • Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. 
  • Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. 
  • Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia. 
  • Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. 
  • Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment. 
  • Undertreatment of obese women receiving breast cancer chemotherapy. 
  • Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. 
  • Urinary biomarkers of oxidative status in a clinical model of oxidative assault. 
  • Using optical spectroscopy to longitudinally monitor physiological changes within solid tumors. 
  • Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. 
  • Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. 
  • Whole body hyperthermia in dogs using a radiant heating device: effect of surface cooling on temperature uniformity. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology